Technology at the service of Parkinson’s disease patients

Following the successful capital raising of BrainHero, we are pleased to announce the funding round of PD Neurotechnology, a Greek MedTech company addressing the second most common neurologic disease: Parkinson's Disease (PD).

This chronic neurodegenerative disease, for which there is no cure, affects an estimated 7 to 10 million people worldwide, up from 2.5 million in 1990.

"PD Monitor® is probably one of the most important steps forward in Parkinson's treatment in recent years and decades." said Per Odin, Professor of Neurology at Lund University, Sweden.

🗓️ This opportunity will be available with priority for selected investors and the SeedBlink Club members (get early access) on August 11, followed by a public launch on August 25.

We're excited to invite you on August 9 for the Pitch & Q&A online event with:

➢ Nikos Moschos - Co-Founder & CEO of PD Neurotechnology

➢ Aristos Doxiadis, Partner at BigPi

➢ Eric Bartha, Deal Captain, SeedBlink

Register now

Why we love PD Neurotechnology

• PDN is a UK-based, ISO 13485 and 27001 certified medical device company founded in 2015.
• In-house, fully developed R&D, manufacturing, support, medical trials, distribution, and sales and marketing functions.
• Patented medical device technology based on AI and machine learning (2 owned, 2 in progress).
• Launched in September 2020, PDMonitor® has generated traction among private patients and hospitals in Europe (G5), Sweden, Ireland, and Cyprus.
• Clinical trials conducted in Germany, Italy, and Greece have confirmed the safety and performance of PDMonitor®, achieving over 95% accuracy in symptom detection.
• Compliance with the Medical Device Directive (MDD - 93/42/EEC). FDA application in advanced progress.
• Strong team expertise and world-class medical advisory board.
• Series A round is led by Digital Health & Technology specialized fund, in North Americal – and joined by Big Pi, a Deeptech VC from Greece. .